
Sleepiz is a company that provides continuous at-home monitoring of sleep and vital parameters using contactless radar technology. Their CE IIa certified medical device, Sleepiz One+, measures movements with sub-millimeter accuracy to analyze breathing patterns, movement, and heartbeats. ML algorithms classify sleep patterns and measure parameters like AHI, Sleep Stages, and WASO. The technology has been validated against polysomnography in clinical trials. Benefits include up to 100x more data sets, high compliance with easy setup and seamless data transmission, and cost savings compared to traditional PSG. The device is used by physicians in routine diagnostics and long-term studies, with users ranging from 20 to over 80 years old. Sleepiz One+ can integrate with optional Bluetooth devices like SpO2 sensors.

Sleepiz is a company that provides continuous at-home monitoring of sleep and vital parameters using contactless radar technology. Their CE IIa certified medical device, Sleepiz One+, measures movements with sub-millimeter accuracy to analyze breathing patterns, movement, and heartbeats. ML algorithms classify sleep patterns and measure parameters like AHI, Sleep Stages, and WASO. The technology has been validated against polysomnography in clinical trials. Benefits include up to 100x more data sets, high compliance with easy setup and seamless data transmission, and cost savings compared to traditional PSG. The device is used by physicians in routine diagnostics and long-term studies, with users ranging from 20 to over 80 years old. Sleepiz One+ can integrate with optional Bluetooth devices like SpO2 sensors.
Headquarters: Zurich, Switzerland
Product: Contactless radar-based at-home sleep and respiration monitoring (Sleepiz One+)
Regulatory status: CE IIa certified medical device; ISO 13485 manufacturer
Founded: 2018
Total funding (disclosed): USD 9,440,000
Employee count (reported): 41
Remote sleep and respiration monitoring, sleep apnea screening, long-term home-based physiological data collection
2018
MedTech / Digital Health
4,400,000
Initial Series A announced CHF 4.4M; later second closing increased Series A total to CHF 6.2M according to company disclosures
1,800,000
Second closing of Series A bringing reported Series A total to CHF 6.2M
Seed round reported on third-party profiles
“Includes venture investors (Verve Ventures), Zürcher Kantonalbank participation, SNGLR Capital AG, a US health-insurance investor, super angels, and public innovation grants (Innosuisse, European Commission)”